Newsroom | 10113 results

ANTONY, Frankrijk--(BUSINESS WIRE)--CAIRDAC, SA, een medtech-bedrijf in de pre-omzetfase dat ALPS™ ontwikkelt – een draadloos, zelfvoedend hartstimulatiesysteem – heeft vandaag de benoeming van de heer Rinda Sama tot lid van de raad van bestuur bekendgemaakt. Zijn benoeming voegt uitgebreide ervaring op het gebied van productie, kwaliteit en bedrijfsvoering toe aan de raad van bestuur en volgt op de recente benoeming van Raymond W. Cohen tot voorzitter. "De uitgebreide ervaring van de heer Sama...

ANTONY, France--(BUSINESS WIRE)--CAIRDAC, SA, une entreprise de technologie médicale en phase de pré-commercialisation qui développe ALPS™, un système de stimulation cardiaque sans sonde et auto-alimenté, a annoncé aujourd’hui la nomination de M. Rinda Sama au sein de son conseil d’administration. Sa nomination apporte au conseil, une solide expérience dans les domaines de la fabrication, de la qualité et des opérations. De même, elle fait suite à la récente nomination de Raymond W. Cohen au po...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--CyberKnife inventor John Adler, MD, wins the 2026 Fogarty Prize for frameless, image-guided radiosurgery, transforming care for more than 1M patients...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyop...

ANTONY, France--(BUSINESS WIRE)--CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable d...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in London. UBS Global Biopharma Conference on Monday, November 16, 2026, from 10:00 a.m. to 10:30 a.m., GMT. Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, from 2:00 p.m. to 2:25 p.m...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. “In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “TRYNGOLZA, our first launch in a large in...

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced that it has won the 2026 MedTech Innovator Mid-Stage Grand Prize, receiving $200,000 in non-dilutive funding. The award recognizes the company's achievements in developing and commercializing vMap®, its FDA-cleared, non-invasive arrhythmia localization technology.MedTech Innovator, the world's largest accelerator of medical technology companies, selected its 2026 cohort...

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being us...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), and interim results from a Phase 1/2a study of investigational ARO-DIMER-PA...